中国生物制药将在2026年CSCO年会展示21项研究结果

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability) Website: www.sbpgroup.com

(Stock code: 1177)

# VOLUNTARY ANNOUNCEMENT 21 RESEARCH RESULTS TO BE PRESENTED AT THE 2026 CSCO ANNUAL MEETING (INCLUDING 5 ORAL PRESENTATIONS)

The board of directors (the “Board”) of Sino Biopharmaceutical Limited (SBP GROUP, together with its subsidiaries, the “Group”) announces that the Group will present 21 latest research results at the 2026 Chinese Society of Clinical Oncology (CSCO) Annual Meeting, including 5 oral presentations. The studies involve the pipeline project TQB3454 (IDH1 inhibitor), as well as marketed products including Anlotinib Capsules (trade name: Fucove®), Benmelstobart Injection (trade name: Andewei®), Efbemalenograstim Alfa Injection (trade name: Ryzneuta®), and Penpulimab Injection (trade name: Anike®), covering multiple therapeutic areas such as pancreatic cancer, lung cancer, renal cell carcinoma, gastrointestinal tumors, soft tissue sarcoma, thyroid cancer, and breast cancer.

### FIVE ORAL PRESENTATIONS

- 1. A Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study of TQB3454 in IDH1-Mutant Advanced Cholangiocarcinoma Corresponding Authors: Shen Lin, Peking University Cancer Hospital; Shen Feng, The Third Affiliated Hospital of Naval Medical University, PLA First Author: Zhou Jun, Peking University Cancer Hospital
- 2. Updated Results of the ALTER-PA-001 Trial: A Multicenter, Open-Label, Randomized Phase II Study of Anlotinib and Benmelstobart in Combination with AG Versus AG Alone as First-Line Treatment for Metastatic Pancreatic Cancer Corresponding Author: Wang Liwei, Renji Hospital, Shanghai Jiao Tong University School of Medicine First Author: Cui Jiujie, Renji Hospital, Shanghai Jiao Tong University School of Medicine


- 3. Serplulimab Plus Anlotinib and Nab-Paclitaxel as Second-Line Treatment for Extensive-Stage Small Cell Lung Cancer After First-Line Chemoimmunotherapy: A Phase II Study Corresponding Author: Wang Jinliang, The Fifth Medical Center of Chinese PLA General Hospital First Author: Zhou Hongrui, The Fifth Medical Center of Chinese PLA General Hospital
- 4. Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study Corresponding Author: Sheng Xinan, Peking University Cancer Hospital First Author: Li Juan, Peking University Cancer Hospital
- 5. Real-World Evidence Supporting Sequential Use of PD-1 after Anlotinib as a Promising Treatment Strategy for Alveolar Soft Part Sarcoma with Lung Metastasis: A Retrospective Cohort Study Corresponding Author: Yan Wangjun, Fudan University Shanghai Cancer Center First Author: Sun Yangbai, Fudan University Shanghai Cancer Center

OTHER PRESENTATIONS

- 6. Case Report: Immune checkpoint inhibitor plus chemotherapy benefited an elderly patient with nonsmall cell lung cancer following EGFR-TKI resistance Corresponding Author: Wang Zhaoxia, The Second Affiliated Hospital of Nanjing Medical University First Author: Liu Zhiyu, The Second Affiliated Hospital of Nanjing Medical University
- 7. Exploration of the Anti-Tumor Effect and Translational Mechanism of Anlotinib Combined with Tislelizumab in the Treatment of Lung Adenocarcinoma Corresponding Author: Yang Zhe, Shandong University First Author: Liao Jiawen, Shandong University
- 8. EGFR p.747_749del mutation enhances Anlotinib sensitivity via upregulating EGR1 and DUSP6 in patients with NSCLC Corresponding Author: Wang Qiming, The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital) First Author: Wu Yufeng, The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital)


- 9. Exploration of the Efficacy and Safety of Anlotinib Combined with Ensartinib for Later-Line Treatment of ALK-Positive NSCLC Corresponding Author: Wang Qiming, The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital) First Author: Li Peng, The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital)
- 10. Clinical Observation and Analysis of Anlotinib Combined with PD-1/PD-L1 as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer Corresponding Author: Wu Chunjiao, Jilin Cancer Hospital First Author: Zhang Xianghua, Jilin Cancer Hospital
- 11. Real-World Study of Anlotinib Combined with Radiotherapy and Immunotherapy for Third-Line and Above Treatment of Advanced Non-Small Cell Lung Cancer Corresponding Author: Wei Man, Bishan Hospital, Chongqing Medical University First Author: Li Yaqian, Bishan Hospital, Chongqing Medical University
- 12. Real-World Study on the Efficacy and Safety of Anlotinib Combined with Nab-Paclitaxel and Temozolomide for Third-Line and Above Treatment of Extensive-Stage Small Cell Lung Cancer with Brain Metastasis Corresponding Author: Liu Ying, Jilin Cancer Hospital First Author: Wei Huafang, Jilin Cancer Hospital
- 13. Integrated Penpulimab, Anlotinib and AG Chemotherapy as First-Line Regimen for Metastatic Pancreatic Cancer: A Multi-Centered, Randomized Controlled Trial (RCT-PAAG) Corresponding Author: Liu Baorui, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School First Author: Du Juan, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School
- 14. Integrated nal-IRI/5-FU/LV, benmelstobart, and anlotinib with or without SBRT for second-line metastatic pancreatic cancer: A phase II dual-cohort study Corresponding Author: Liu Baorui, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School First Author: Du Juan, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School


- 15. Cost-Effectiveness Analysis of Anlotinib plus Penpulimab versus Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma Corresponding Author: Du Qiong, Fudan University Shanghai Cancer Center First Author: Luo Jiefeng, Fudan University Shanghai Cancer Center
- 16. Analysis of Short-Term Efficacy and Safety of Transcatheter Chemoembolization Infusion (iTACE) Combined with Anlotinib for the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma Corresponding Author: Xu Ke, The First Affiliated Hospital of Chengdu Medical College First Author: Liu Tao, The First Affiliated Hospital of Chengdu Medical College
- 17. Neoadjuvant Anlotinib plus Sintilimab for RET-Fusion Anaplastic Thyroid Carcinoma Corresponding Author: Zhang Bin, Peking University Cancer Hospital First Author: Song Yuntao, Peking University Cancer Hospital
- 18. Efficacy and Safety of Anlotinib Combined Regimens in the Treatment of Advanced Breast Cancer: A Real-World Study Corresponding Author: Yao Jing, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology First Author: Li Yuting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- 19. Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis Corresponding Author: Tu Zhongqi, West China Hospital, Sichuan University First Author: Zhou Yong, West China Hospital, Sichuan University
- 20. Anlotinib Regulates Macrophage Reprogramming to inhibit tumor progression efficacy Corresponding Author: Zhang Hongmei, Xijing Hospital, Air Force Medical University First Author: Chao Xiaoting, Xijing Hospital, Air Force Medical University


- 21. Efbemalenograstim Alfa versus PEG rhG-CSF for Preventing Chemotherapy-Induced Neutropenia in Locally Advanced Nasopharyngeal Carcinoma: A Propensity Score Matched Retrospective Study Corresponding Author: Luo Haiqing, The Affiliated Hospital of Guangdong Medical University First Author: Cai Yilin, The Affiliated Hospital of Guangdong Medical University


Hong Kong, 30 July 2026

By order of the Board Sino Biopharmaceutical Limited Tse, Theresa Y Y

## Chairwoman

## As at the date of this announcement, the Board of the Company comprises five executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.